Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oxycodone with an opioid receptor antagonist: A review.

Journal of opioid management·2016

Same author

Then and now … HIV consultation psychiatry update.

Advances in psychosomatic medicine·2015

Same author

Treatment of fatigue and sleep disorders in cancer patients.

Cancer journal (Sudbury, Mass.)·2014

Same author

Long-term and short-term effects of insomnia in cancer and effective interventions.

Cancer journal (Sudbury, Mass.)·2014

Same author

A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain.

Sleep·2014

Same author

Oxycodone combined with opioid receptor antagonists: efficacy and safety.

Expert opinion on drug safety·2013

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia

Published on: April 19, 2024

Hydromorphone-OROS formulation.

Harold W Goforth¹

¹Duke University Medical Center, DUMC 3309, Durham, NC 27710, USA. harold.goforth@duke.edu

Expert Opinion on Pharmacotherapy

|April 21, 2010

Summary

Extended-release hydromorphone using OROS technology offers effective long-acting pain control. This formulation presents safety advantages over previous extended-release hydromorphone options.

Area of Science:

Pharmacology
Pain Management
Drug Delivery Systems

Background:

Hydromorphone is a semi-synthetic opioid used for moderate to severe pain.
Current formulations are short-acting, with no extended-release option available.
Previous extended-release hydromorphone formulations were withdrawn due to safety concerns.

Purpose of the Study:

To review the use of an extended-release hydromorphone formulation utilizing OROS technology.
To highlight the safety advantages of this new formulation.

Main Methods:

Literature review of Medline articles on 'hydromorphone and OROS'.
Analysis of regulatory affairs data.
Review of physician prescribing information.

More Related Videos

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia

Surgical Technique of the 3-Dimensional-printed Personalized Hip Implant for the Treatment of Canine Hip Dysplasia

Published on: April 19, 2024

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Urethral Stricture Induction Followed by Buccal Mucosa Graft Urethroplasty in a Rat Model

Published on: April 28, 2023

Main Results:

The OROS technology enables an extended-release hydromorphone formulation.
This technology offers safety advantages compared to prior extended-release hydromorphone products.
Increased understanding of the application and benefits of hydromorphone-OROS.

Conclusions:

Hydromorphone-OROS provides effective long-acting pain management.
It is a valuable addition to existing opioid formulations for pain relief.